Inhaled human insulin. No short-term advantages, too many unknowns in the long term

Prescrire International

Volumn 15, Issue 86, 2006, Pages 203-209

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SALBUTAMOL; SULFONYLUREA DERIVATIVE;

ARTICLE; BODY WEIGHT DISORDER; CIGARETTE SMOKING; CLINICAL TRIAL; COUGHING; DIABETES CONTROL; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG PREFERENCE; DRUG SENSITIVITY; DRUG STORAGE; DYSPNEA; EPISTAXIS; EXPIRATORY FLOW RATE; HEMOGLOBIN DETERMINATION; HUMAN; HUMIDITY; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LARYNGITIS; LONG TERM CARE; LUNG FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; POWDER; PREGNANCY; RETINA HEMORRHAGE; RHINITIS; RISK BENEFIT ANALYSIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; EUROPE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; POWDERS; RANDOMIZED CONTROLLED TRIALS;

EID: 37849188049     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Prescrire Editorial Staff "Insulin in type 2 diabetes" Prescrire Int 2005; 14 (79): 187-183.
2. U.S. Food and Drug Administration - CDR "Clinical pharmacology and biopharmaceutics review (executive summary for advisory committee) NDA 21-868" 10 August 2005. Website http://www.fda.gov accessed 13/09/ 05: 9 pages.
3. Rave K et al. "Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin" Diabetes Care 2005; 28 (5): 1077-1082.
4. U.S. Food and Drug Administration "NDA 21-868/Exubera°. US Package Insert" 27/01/2006: 24 pages.
5. European Medicines Agency - CHMP "European Public Assessment Report (EPAR) - Exubera (first published) - Scientific Discussion" 57 pages; published online on 7 April 2006.
6. U.S. Food and Drug Administration "Initial clinical review for inclusion in advisory committee briefing document. NDA 21-868" 4 August 2005. Website http://www.fda.gov accessed 13/09/05: 294 pages.
7. Diabetes Control and Complications Trial research group "Implementation of treatment protocols in the diabetes control and complications trial" Diabetes Care 1995; 18(3): 361-376.
8. Skyler JS et al. "Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects. A 6-month, randomized, comparative trial" Diabetes Care 2005; 28 (7): 1630-1635.
9. U.S. Food and Drug Administration "Statistical review and evaluation. Clinical studies. NDA 21-868" 2005. Website http://www.fda.gov accessed 13/09/05: 52 pages.
10. Norwood P et al. "Inhaled insulin (Exubera°) achieves tight glycemic control and is well tolerated in patients with type 1 diabetes" Oral presentation to the European Association for Study of Diabetes 2005, Athens September 2005: Abstract 73. Accessed 10/02/05 on www.easd.org: 1 page.
11. Black C et al. "The clinical effectiveness and cost effectiveness of inhaled insulin in diabetes mellitus: A systematic review and economic evaluation" January 2006: 163 pages.
12. Quattrin T et al. "Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Results of a 6-month, randomized, comparative trial" Diabetes Care 2004; 27(11): 2622-2627.
13. Skyler JS et al. "Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study" Lancet 2001; 357: 331-335.
14. de Fronzo RA et al. "Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. A 12-week, randomized, comparative trial" Diabetes Care 2005; 28 (8): 1922-1928.
15. Weiss SR et al. "Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents. A randomized controlled trial" Arch Intern Med 2003; 163: 2277-2282.
16. Rosenstock J et al. "Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. A randomized, controlled trial" Ann Intern Med 2005; 143 (8): 549-558.
17. Hollander PA et al. "Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Results of a 6-month, randomized, comparative trial" Diabetes Care 2004; 27 (10): 2356-2362.
18. Cefalu WT et al. "Inhaled human insulin treatment in patients with type 2 diabetes mellitus" Ann Intern Med 2001; 134: 203-207.
19. Rosenstock J et al. "Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes" Diabetes Care 2004; 27 (6): 1318-1323.
20. Cappelleri JC et al. "Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen" Clin Ther 2002; 24 (4): 552-564.
21. Pfizer "Advisory committee briefing document. Exubera°" 8 September 2005. Website http://www.fda.gov accessed 13/09/05: 232 pages.
22. Cefalu WT "Inhaled insulin: A proof-of-concept study" Ann Intern Med 2001; 134 (9 part 1): 795.
23. U.S. Food and Drug Administration "Division of pulmonary and allergy drug products. Briefing package review. NDA 21-868" 11 August 2005. Website http://www.fda.gov accessed 13/09/05: 149 pages.
24. Prescrire Rédaction "Aggravation paradoxale de la rétinopathie diabétique liée à la normalisation glycémique" Rev Prescrire 2000; 20 (204): 219.
25. European Commission "SPC - Exubera" 21 March 2006: 17 pages.
26. U.S. "Letter (to Pfizer)" Department of Health & Human Services 27/01/2006. Website http://www.fda.gov accessed 12 May 2006: 10 pages.
27. Becker RHA et al. "The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin" Diabetes Care 2006; 29 (2): 277-282.
28. European Commission "Leaflet - Exubera" 21 March 2006: 22 pages.
29. Gerber RA et al. "Treatment satisfaction with inhaled insulin in patients with type 1 diabetes. A randomized controlled trial" Diabetes Care 2001; 24 (9): 1556-1559.